⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
IN-207907 Injection for Sarcopenia
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-13 — CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy: cross-connection with aav-follistatin-gene-therapy: Both are early-phase injectable interventions targeting age-related muscle loss; AAV9-follistatin (± VEGF plasmid) pursues durable myostatin-pathway blockade via gene delivery, whereas IN-207907 is a conventional injectable sarcopenia therapeutic — parallel but distinct modalities on the same sarcopenia endpoint. (novelty: 4)
- 2026-06-25 — A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia: Placebo-controlled dose-ranging trial (120 / 240 / 360 mg) launched in elderly sarcopenia patients with SPPB as primary endpoint; trial registered, no readout yet. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia
25-jun-2026
novelty 3
per-area 3
strengthens